HEPATOKIN1 is a biochemistry-based model of liver metabolism for applications 
in medicine and pharmacology

Berndt, Nikolaus; Bulik, Sascha; Wallach, Iwona; Wünsch, Tilo; König, Matthias; Stockmann, Martin; Meierhofer, David; Holzhütter, Hermann-Georg

doi:10.1038/s41467-018-04720-9

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

HEPATOKIN1 is a biochemistry-based model of liver metabolism for applications in medicine and pharmacology

MPS-Authors

/persons/resource/persons50427

Meierhofer, David
Mass Spectrometry (Head: David Meierhofer), Scientific Service (Head: Christoph Krukenkamp), Max Planck Institute for Molecular Genetics, Max Planck Society;

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

Berndt.pdf
(出版社版), 3MB

付随資料 (公開)

There is no public supplementary material available

引用

Berndt, N., Bulik, S., Wallach, I., Wünsch, T., König, M., Stockmann, M., Meierhofer, D., & Holzhütter, H.-G. (2018). HEPATOKIN1 is a biochemistry-based model of liver metabolism for applications in medicine and pharmacology. Nature Communications, 9:. doi:10.1038/s41467-018-04720-9.

引用: https://hdl.handle.net/21.11116/0000-0001-8563-9

要旨

The epidemic increase of non-alcoholic fatty liver diseases (NAFLD) requires a deeper understanding of the regulatory circuits controlling the response of liver metabolism to nutritional challenges, medical drugs, and genetic enzyme variants. As in vivo studies of human liver metabolism are encumbered with serious ethical and technical issues, we developed a comprehensive biochemistry-based kinetic model of the central liver metabolism including the regulation of enzyme activities by their reactants, allosteric effectors, and hormone-dependent phosphorylation. The utility of the model for basic research and applications in medicine and pharmacology is illustrated by simulating diurnal variations of the metabolic state of the liver at various perturbations caused by nutritional challenges (alcohol), drugs (valproate), and inherited enzyme disorders (galactosemia). Using proteomics data to scale maximal enzyme activities, the model is used to highlight differences in the metabolic functions of normal hepatocytes and malignant liver cells (adenoma and hepatocellular carcinoma).